Prometheus Biosciences, Inc. RXDX
Set alert
199.92 +199.92 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 9.56B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -44.33
- Beta
- -0.49
- Short ratio
- 3.97
- Inst. own
- 81.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 10, 2023
- 50-d avg
- 189.46
- 200-d avg
- 112.93
- 1y target
- 190.00
Analyst view
Consensus: buy
Buy
Price target (mean) 190.00 -5.0% downside
Now 199.92
- Target (low)
- 160.00
- Target (mean)
- 190.00
- Target (high)
- 200.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 9
- 2 months ago 10
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.94 | -0.99 – -0.89 | -0.86 | -9.3% | 900.00K | -29.1% | 2 |
| Next quarter | -0.99 | -1.06 – -0.93 | -0.90 | -10.0% | 970.00K | +0.2% | 2 |
| Current year | -3.99 | -4.34 – -3.64 | -3.49 | -14.3% | 4.15M | -39.1% | 2 |
| Next year | -4.51 | -4.83 – -4.19 | -3.99 | -13.0% | 3.75M | -9.6% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 10, 2023 | RBC Capital | Maintained | — | Sector Perform |
| May 10, 2023 | Jefferies | Downgrade | Buy | Hold |
| Apr 18, 2023 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Apr 18, 2023 | Credit Suisse | Downgrade | Outperform | Neutral |
| Apr 18, 2023 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Apr 18, 2023 | Piper Sandler | Downgrade | Overweight | Neutral |
| Apr 17, 2023 | Guggenheim | Downgrade | Buy | Neutral |
| Apr 17, 2023 | Stifel | Downgrade | Buy | Hold |
| Mar 6, 2023 | Guggenheim | Maintained | — | Buy |
| Mar 1, 2023 | Credit Suisse | Maintained | — | Outperform |
| Mar 1, 2023 | Oppenheimer | Maintained | — | Outperform |
| Jan 31, 2023 | Goldman Sachs | Maintained | — | Buy |
| Dec 8, 2022 | Credit Suisse | Maintained | — | Outperform |
| Dec 8, 2022 | BTIG | Maintained | — | Buy |
| Dec 8, 2022 | Oppenheimer | Maintained | — | Outperform |
| Dec 8, 2022 | RBC Capital | Maintained | — | Outperform |
| Nov 1, 2022 | Stifel | Maintained | — | Buy |
| Oct 4, 2022 | Oppenheimer | Maintained | — | Outperform |
| Oct 4, 2022 | RBC Capital | Maintained | — | Outperform |
| Oct 3, 2022 | BTIG | Maintained | — | Buy |
| Aug 29, 2022 | Piper Sandler | Maintained | — | Overweight |
| Aug 29, 2022 | Wells Fargo | Maintained | — | Overweight |
| Aug 12, 2022 | Credit Suisse | Maintained | — | Outperform |
| Aug 12, 2022 | SVB Leerink | Maintained | — | Outperform |
| Jul 20, 2022 | Goldman Sachs | Initiated | — | Buy |
| Jun 10, 2022 | Piper Sandler | Initiated | — | Overweight |
| May 13, 2022 | RBC Capital | Maintained | — | Outperform |
| May 13, 2022 | Wells Fargo | Maintained | — | Overweight |
| Mar 10, 2022 | Credit Suisse | Maintained | — | Outperform |
| Mar 10, 2022 | Wells Fargo | Maintained | — | Overweight |